Implantable Pacemaker Articles & Analysis
16 news found
Implicity’s AI-powered* platform allows healthcare professionals to better manage the growing streams of patient information produced by cardiac implantable electronic devices (CIEDs), such as pacemakers and implanted defibrillators. ...
“EBR’s WiSE leadless pacemaker technology is one of the most exciting cardiology technologies in development, and it is fantastic that more Australian investors can now back it,” says Dr. ...
“The effects on ISH and Pulse Pressure are especially compelling given the prevalence of this particularly challenging form of hypertension in our initial target population of hypertensive patients indicated for a permanent pacemaker implant. We look forward to communicating next steps as we work to advance BackBeat CNT into definitive studies and towards ...
The editorial can be accessed here. Over 1.1 million pacemakers are implanted annually worldwide.1 Patients indicated for a pacemaker have a particularly high rate of elevated blood pressure with more than 70% of these patients suffering from hypertension.2 Based on data from the National Health and Nutrition Examination Survey (NHANES) III, it ...
Fourteen year-old Sedarius was recently featured on WSB-TV Atlanta as the first pediatric patient to receive surgery to implant a diaphragm pacemaker in the state of Georgia. Sedarius was diagnosed with CCHS when he was eight years old, and required a tracheotomy and ventilator to breathe while he slept. The Avery Breathing Pacemaker will allow ...
After neurosurgery, Endomedix plans to target hemostasis indications for cardiac pacemaker and implanted defibrillator procedures. As an example of the potential scope of the technology, Endomedix has recently entered into a Cooperative Research And Development Agreement (CRADA) with the US Army using PLEXimine to develop a treatment for Ocular Projectile ...
” All patients enrolled in the MODERATO II study, a European prospective, multi-center, double-blind, randomized study of BackBeat CNT vs. control in 47 patients with persistent hypertension (ASBP ≥130 mmHg and office systolic blood pressure (OSBP) ≥ 140 mmHg) despite one or more anti-hypertensive medications and a pacemaker indication, were ...
The study confirmed the Tempo Lead is safe and effective for temporary cardiac pacing, provides stable peri- and post-procedural pacing support, and facilitates post-procedure ambulation, which can safely allow direct transfer to step-down or telemetry units with no ICU time required, reducing length of stay.3 In addition, the Tempo Lead allows watchful waiting after procedures, potentially ...
N8 Medical, LLC (N8 Medical) today announced that the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) indicated its intent to fund N8 Medical’s STTR Phase I grant application for the development of a resorbable envelope to prevent surgical site infections associated with pacemaker implantation surgeries. N8 ...
This module was designed for -100 to 330 °C temperature monitoring in medical magnetic resonance imaging (MRI) and radio frequency (RF) OEM systems, implantable device testing, and general-purpose research and development labs. ...
The study confirmed the Tempo Lead is safe and effective for temporary cardiac pacing, provides stable peri- and post-procedural pacing support, and facilitates post-procedure ambulation, which can safely allow direct transfer to step-down or telemetry units with no ICU time required, reducing length of stay.3 In addition, the Tempo Lead allows watchful waiting after procedures, potentially ...
The WiSE system works together with a previously implanted pacemaker or implantable cardioverter defibrillator (ICD) that paces the right side of the heart. ...
Study participants have been followed for more than three years and have demonstrated consistent positive outcomes, including no observed stroke, no pacemaker implantations, virtually no paravalvular leak (PVL), and a high retained average effective orifice area (EOA) >2.2cm2. ...
Study participants have been followed for more than three years and have demonstrated consistent positive outcomes, including no observed stroke, no pacemaker implantations, virtually no paravalvular leak (PVL), and a high retained average effective orifice area (EOA) >2.2cm2. ...
“We have a unique approach to adding proven antimicrobial capabilities to new or existing medical devices and implants, one that does not require external power sources, does not use drugs or other pharmaceutical agents and is durable enough to withstand the abrasive forces of screwing into bone. With these latest allowances, our IP portfolio has expanded to protect the use ...
This uniquely allows us to protect the broad range of our antimicrobial devices from orthopedic screws, hip and knee prostheses and cardiac implantable defibrillators and pacemakers to venous access indwelling catheters, sutures, surgical mesh and even surgical ...